<DOC>
	<DOCNO>NCT02561442</DOCNO>
	<brief_summary>The propose study aim assess time MIC ( 4 mg/mL ) , pharmacokinetics/pharmacodynamics bioavailability 1 g ceftriaxone administer constant rate subcutaneous infusion 2 hour compare 1 g ceftriaxone administer constant IV infusion 0.5 hour . In addition , study compare result obtain 1 g ceftriaxone intravenous subcutaneous administration 2 g ceftriaxone administer subcutaneously</brief_summary>
	<brief_title>Crossover Study Compare Pharmacokinetics Subcutaneous Intravenous Ceftriaxone Administration</brief_title>
	<detailed_description />
	<mesh_term>Ceftriaxone</mesh_term>
	<criteria>1 . An Institutional Review Board ( IRB ) approve informed consent sign date prior studyrelated activity . 2 . Male female subject 18 65 year age inclusive . 3 . Subjects must body weight 45.5 105 kg inclusive body mass index ( BMI ) ≤34 kg/m2 . 4 . Females nonpregnant , nonlactating , either postmenopausal least 1 year , surgically sterile ( e.g. , tubal ligation , hysterectomy ) least 90 day , agree , time signing inform consent 14 day prior Baseline Followup , use TWO ( 2 ) follow forms contraception : IUD spermicide , female condom spermicide , contraceptive sponge spermicide , intravaginal system , diaphragm spermicide , cervical cap spermicide , male sexual partner agree use male condom spermicide , sterile sexual partner , OR abstinence . For female , pregnancy test result must negative Screening Baseline/Day 0 5 . Males agree time Baseline/Day 0 Followup , use TWO ( 2 ) form contraception : ONE must male condom spermicide ; second may ONE following : female partner use either IUD spermicide , female condom spermicide , contraceptive sponge spermicide , intravaginal system , diaphragm spermicide , cervical cap spermicide , oral contraceptive ; OR abstinence 6 . Subject normal ( abnormal clinically insignificant ) laboratory value screen . 7 . Subject medically normal significant abnormal finding Baseline physical examination . 8 . Subjects must Baseline value follow laboratory test specify : AST , ALT , alkaline phosphatase ( ALP ) , total bilirubin , creatinine &lt; 1.1 ULN Platelet count &gt; 100 X 103/µL Neutrophil count &gt; 1.0 X 103/µL 9 . Subject ability understand requirement study willing comply study procedure . 10 . Subject consume agrees abstain take vitamin dietary supplement nonprescription drug ( except authorize Investigator Medical Monitor ) 3 day prior CRU admission FollowUp , exception oral contraceptive . 11 . Subject consume agrees abstain take prescription drug ( except authorize Investigator Medical Monitor ) 14 day prior CRU admission FollowUp . 12 . Subject consume agrees abstain consume grapefruit , grapefruit juice , juice contain grapefruit , Seville oranges 3 day prior CRU admission FollowUp . 13 . Subject agree abstain use alcohol 48 hour prior Screening CRU admission CRU discharge period . 1 . Evidence history clinically significant oncologic , pulmonary , hepatic , gastrointestinal , cardiovascular , hematologic , metabolic , neurological , immunologic , nephrologic , endocrine , psychiatric disease , current clinically significant infection . 2 . History chronic skin condition require medical therapy . 3 . Clinically significant abnormality Screening Baseline safety laboratory test . 4 . Corrected QT interval ( QTc ) great 450 msec male 470 msec female correct Fridericia formula . 5 . Major surgery within 30 day prior Screening . 6 . Administration investigational drug implantation investigational device , participation another trial , within 30 day prior Screening . 7 . Any surgical medical condition opinion investigator may interfere participation study may affect outcome study . 8 . Positive test hepatitis B , hepatitis C , HIV Screening . 9 . Positive urine drug screen Screening Baseline . 10 . Tobacco user ( include user stop smoke £90 day prior screen evaluation ) . [ Note : `` Tobacco use '' include smoking use snuff chew tobacco , nicotine nicotine containing product . ] 11 . History alcohol abuse within 6 month prior screen , determine Investigator . 12 . Consumed alcohol within 48 hour Screening CRU admission positive alcohol test Screening admission CRU . 13 . Known allergy cephalosporin class antibiotic penicillin . 14 . Female subject pregnant lactating . 15 . Donation great 100 mL either whole blood plasma within 30 day prior study drug administration . 16 . Subjects hemoglobin ( Hb ) ≤10.5 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>